Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 17, 2001
Grant Date -
N/A
app pub date -
Jun 7, 1995
filing date -
Sep 15, 1988
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully